88 related articles for article (PubMed ID: 26492706)
1. [Efficacy and costs of ovarian cancer therapy in Poland--regional approach].
Kozierkiewicz A; Jach R; Basta T; Śliwczyński A; Tomczyk R; Jędrzejczyk T
Ginekol Pol; 2015 Aug; 86(8):582-9. PubMed ID: 26492706
[TBL] [Abstract][Full Text] [Related]
2. [Costs of population cervical cancer screening program in Poland between 2007-2009].
Spaczyński M; Karowicz-Bilinska A; Kedzia W; Molińska-Glura M; Seroczyński P; Januszek-Michalecka L; Rokita W; Nowak-Markwitz E
Ginekol Pol; 2010 Oct; 81(10):750-6. PubMed ID: 21117303
[TBL] [Abstract][Full Text] [Related]
3. Comparison of economic and health implications from earlier detection of HIV infection in the United Kingdom and Poland.
Zah V; Toumi M
Przegl Epidemiol; 2015; 69(4):765-72, 899-903. PubMed ID: 27139359
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review.
Kim K; Hernlund E; Hernadi Z; Révész J; Pete I; Szánthó A; Bodnar L; Madry R; Timorek-Lemieszczuk A; Bozanovic T; Vasovic S; Tomasevic Z; Zivaljevic M; Pazin V; Minárik T; Garanová H; Helpianska L; Justo N
Int J Gynecol Cancer; 2013 Jun; 23(5):823-32. PubMed ID: 23666016
[TBL] [Abstract][Full Text] [Related]
5. [The costs of asthma in Poland in 2012].
Jahnz-Różyk K; Kucharczyk A; Warchoł M; Radziwilska-Muc A; Władysiuk M; Plisko R
Pol Merkur Lekarski; 2015 Aug; 39(230):91-5. PubMed ID: 26319382
[TBL] [Abstract][Full Text] [Related]
6. The economic impact of false-positive cancer screens.
Lafata JE; Simpkins J; Lamerato L; Poisson L; Divine G; Johnson CC
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2126-32. PubMed ID: 15598770
[TBL] [Abstract][Full Text] [Related]
7. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
8. [Survival of cervical cancer patients in selected regions of Poland in 1990-1996, in relation to some prognostic factors].
Bielska-Lasota M; Krynicki R; Rabczenko D; Czerw-Głab K; Starzewski J; Wronkowski Z; Zieliński J; Chil A; Hudała-Klecha J; Swiercz A
Przegl Epidemiol; 2004; 58(3):523-36. PubMed ID: 15730017
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting.
Kawalec P; Holko P; Stawowczyk E; Borowiec Ł; Filipiak KJ
Kardiol Pol; 2015; 73(9):768-80. PubMed ID: 25987296
[TBL] [Abstract][Full Text] [Related]
10. [Treatment costs of malignant cervical cancer in Poland in 2011-2012--the case of Silesian Voivodeship].
Holecki T; Sobczyk K; Nawrocki S; Woźniak-Holecka J; Skrzypek M; Bocionek A
Ginekol Pol; 2015 Nov; 86(11):849-55. PubMed ID: 26817317
[TBL] [Abstract][Full Text] [Related]
11. Production lost due to cervical cancer in Poland in 2012.
Dubas-Jakóbczyk K; Kocot E; Seweryn M; Koperny M
Med Pr; 2016; 67(3):289-99. PubMed ID: 27364103
[TBL] [Abstract][Full Text] [Related]
12. Societal costs of ovarian cancer in a population-based cohort - a cost of illness analysis.
Palmqvist C; Persson J; Albertsson P; Dahm-Kähler P; Johansson M
Acta Oncol; 2022 Nov; 61(11):1369-1376. PubMed ID: 36326583
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.
Poonawalla IB; Lairson DR; Chan W; Piller LB; Du XL
Value Health; 2015 Jun; 18(4):387-95. PubMed ID: 26091592
[TBL] [Abstract][Full Text] [Related]
14. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
Armstrong A; Otvos B; Singh S; Debernardo R
Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
[TBL] [Abstract][Full Text] [Related]
16. [Screening for ovarian cancer].
Bjørge T; Dørum A; Tropé CG
Tidsskr Nor Laegeforen; 2000 May; 120(12):1444-8. PubMed ID: 10851943
[TBL] [Abstract][Full Text] [Related]
17. Resource utilization for ovarian cancer patients at the end of life: how much is too much?
Lewin SN; Buttin BM; Powell MA; Gibb RK; Rader JS; Mutch DG; Herzog TJ
Gynecol Oncol; 2005 Nov; 99(2):261-6. PubMed ID: 16140364
[TBL] [Abstract][Full Text] [Related]
18. [Attempted assessment of the incidence and cost of surgical treatment of inginal hernias in Poland in the years 2001-2002].
Pierściński S; Szopinśki J; Szmytkowski J; Dabrowiecki S
Przegl Epidemiol; 2005; 59(4):981-6. PubMed ID: 16729440
[TBL] [Abstract][Full Text] [Related]
19. The burden of Herpes Zoster and its complications in Poland in according to the age.
Albrecht P; Patrzałek M; Goryński P
Przegl Epidemiol; 2015; 69(4):693-7, 841-3. PubMed ID: 27139346
[TBL] [Abstract][Full Text] [Related]
20. [Model for the regional allocation of the National Health Care Fund].
Loreti P; Muzzi A; Bruni G
Ann Ig; 1989; 1(1-2):195-218. PubMed ID: 2483067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
